Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [14C]-Praliciguat in Healthy Male Subjects
NCT03818295Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of praliciguat in diabetic nephropathy (DN) and heart failure with preserved ejection fraction (HFpEF), sponsored by Cyclerion Therapeutics. Primary endpoints: Amount of total radioactivity excreted in urine, Amount of total radioactivity excreted in feces and 6 more. Started Mar 2019; status: completed.
02
Drugs
praliciguat
03
Conditions
diabetic nephropathy (DN)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03818295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818295.